ArticleNeurology and therapy2023

Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.

Ataru Igarashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.